NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma.

ABSTRACT:

Introduction

Glioblastoma multiforme (GBM) is the most common primary central nervous (CNS) system malignancy with a poor prognosis. The standard treatment for GBM is neurosurgical resection, followed by radiochemotherapy and adjuvant temozolomide chemotherapy. Predictive biomarkers, such as methylation of the promoter region of the O6-methylguanine DNA methyltransferase (MGMT) gene, can successfully distinguish subgroups with different prognosis after temozolomide chemotherapy. Based on multiomics studies, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), BRAF V600E mutation, neurotrophic tyrosine receptor kinase (NTRK) fusions and other potential therapy targets have been found.

Methods

We have reviewed the preclinical and clinical evidenc

SUBMITTER: Wang Y 

PROVIDER: S-EPMC7734330 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature